Citadel Advisors
WVE icon

Citadel Advisors’s Wave Life Sciences WVE Stock Holding History

Citadel Advisors’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84M Sell
253,300
-519,400
-67% -$6.77M ﹤0.01% 6257
2025
Q4 		$13.1M Buy
772,700
+662,900
+604% +$6.74M ﹤0.01% 2880
2025
Q3 		$804K Buy
+109,800
New +$888K ﹤0.01% 8023
2025
Q2 		– Sell
-36,500
Closed -$295K – 15376
2025
Q1 		$295K Sell
36,500
-32,700
-47% -$358K ﹤0.01% 9645
2024
Q4 		$856K Buy
69,200
+58,800
+565% +$785K ﹤0.01% 7380
2024
Q3 		$85.3K Sell
10,400
-3,800
-27% -$22.7K ﹤0.01% 11332
2024
Q2 		$70.9K Sell
14,200
-13,800
-49% -$78.7K ﹤0.01% 11362
2024
Q1 		$173K Buy
28,000
+12,800
+84% +$64.1K ﹤0.01% 10551
2023
Q4 		$76.8K Buy
+15,200
New +$81.2K ﹤0.01% 11273
2023
Q3 		– Sell
-8,700
Closed -$31.7K – 15229
2023
Q2 		$31.7K Buy
8,700
+800
+10% +$3.23K ﹤0.01% 12291
2023
Q1 		$34.2K Sell
7,900
-11,100
-58% -$50.9K ﹤0.01% 12602
2022
Q4 		$133K Sell
19,000
-4,200
-18% -$19.4K ﹤0.01% 10794
2022
Q3 		$84K Sell
23,200
-600
-3% -$1.99K ﹤0.01% 11242
2022
Q2 		$77K Buy
+23,800
New +$45.8K ﹤0.01% 11629
2022
Q1 		– Sell
-12,400
Closed -$39K – 14710
2021
Q4 		$39K Sell
12,400
-16,500
-57% -$68.5K ﹤0.01% 13386
2021
Q3 		$142K Sell
28,900
-4,700
-14% -$28.5K ﹤0.01% 12443
2021
Q2 		$224K Sell
33,600
-35,200
-51% -$230K ﹤0.01% 11918
2021
Q1 		$386K Buy
68,800
+52,400
+320% +$503K ﹤0.01% 10272
2020
Q4 		$129K Sell
16,400
-27,400
-63% -$230K ﹤0.01% 10045
2020
Q3 		$372K Sell
43,800
-13,500
-24% -$148K ﹤0.01% 7782
2020
Q2 		$596K Sell
57,300
-27,100
-32% -$255K ﹤0.01% 6756
2020
Q1 		$791K Sell
84,400
-45,300
-35% -$386K ﹤0.01% 5723
2019
Q4 		$1.04M Buy
+129,700
New +$3.18M ﹤0.01% 5508
2019
Q3 		– Sell
-12,100
Closed -$316K – 9827
2019
Q2 		$316K Sell
12,100
-6,900
-36% -$193K ﹤0.01% 7514
2019
Q1 		$738K Buy
+19,000
New +$771K ﹤0.01% 6126

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors's WVE Position: Q1 2026 in Review

Citadel Advisors increased its Wave Life Sciences (WVE) stake by 179% in Q1 2026, buying an estimated $18.4M and bringing the position to 2,202,856 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Citadel Advisors first reported a position in WVE in Q1 2018 and has held it in 25 quarters since. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Citadel Advisors held 2,202,856 shares of Wave Life Sciences worth $16M as of Q1 2026.
  • Citadel Advisors bought 1,412,892 Wave Life Sciences shares in Q1 2026, an estimated $18.4M.
  • Wave Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2611 holding.
  • Citadel Advisors first reported a position in Wave Life Sciences in Q1 2018 and has held it in 25 quarters since.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.